Clinical Trial Update: Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 trial of SNA-120 for pruritus in patients with psoriasis vulgaris; the update reports safety, efficacy, and tolerability findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• SNA-120

Snippet

Sponsor: Sienna Biopharmaceuticals | Conditions: Pruritus, Psoriasis Vulgaris | Phase 2 | Status: COMPLETED